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BOOK REVIEW way to manipulate grafts to minimize GVHD while pre-transplants show higher peritransplant and nonrelapse mortality compared with sibling donor approaches. Hap-serving immunologic integrity is to fight infection and destroy residual tumors.
loidentical SCT is an acceptable therapeutic option for patients with hematologic malignancies who have the Conditioning for SCT by chemotherapy, irradiation, cytokines, and anti-T-cell antibodies is complicated by greatest need for transplants but do not have a matched sibling donor. Haploidentical recipients are serotyped serious infections, which are the primary impediments for survival after SCT. In the preengraftment period in-with family members to identify donor-recipient pairs who inherit in common a sixth chromosome containing fection risk is high with profound granulocytopenia and mucosits, and in the posttransplant period complicated the MHC complex that mainly regulates immune response (2). Haploidentical donors and recipients are generally by fungal and viral infections like CMV and EBV posttransplant immune proliferative disease. This can be at-found to be variably mismatched for the major transplant antigens: HLA-A, -B, and -DR. Advantages of tenuated by a combination of B-and T-cell depletion as a preemptive therapy in patients with high EBV DNA haploidentical SCT include rapid and universal access to donors; complications of haploidentical SCT are simi-load and risk factors. Intensive immunotherapy includes rituximab alone or in combination with other mono-lar to transplants using an unrelated alternative donor. The third part of the book provides readers with a clonal antibodies like anti-IL-6.
In addition to GVHD, pulmonary toxicity is consid-valuable reference for alternative sources for donor stem cells. In addition to bone marrow stem cells, peripheral ered a most serious side effect of stem cell transplantation. Pulmonary dysfunction and diffuse lung injury blood stem cells (PBSC) are steadily becoming the standard care for stem cell therapy, especially in the autolo-occur in 25-55% of HSC transplant recipients, and account for approximately 50% of transplant-related mor-gous setting. Circulating blood stem cells represent less than 0.001% of all nucleated cells in circulation (1). tality. Both pulmonary infections as well as noninfectious pulmonary toxicity, which may be related to GVHD, in-Recruitment of progenitor HSCs rises dramatically in response to rhCSFs (G-CSF, and GM-CSs). Ease of col-fluence mortality in the immediate posttransplant period and could cause severe morbidity in the delayed post-lection and rapid engraftment are rendering PBSC increasingly popular also in the allogeneic setting. PBSCT transplant period. Standard therapy includes immunosuppression in conjunction with supportive care of supple-requires less time for stable neutrophil and platelet engraftment than bone marrow SCT, and there is a trend mental oxygen therapy and broad spectrum antimicrobial prophylaxis. High mortality is associated with severe towards improved survival after PBSCT. However, a major limitation is a higher incidence of acute and chronic disease. Hepatic venoocclusive disease is another serious complication of HSCT that occurs typically at day GVHD with decreased relapse rate but potential negative impact on survival. The introduction of novel im-30 posttransplantation as a manifestation of the conditioning regimens, particularly chemotherapy. It is char-munosuppressive medications such as sirolimus and mycophenolate mofetil may allow more extensive use of acterized by liver enlargement and pain, fluid retention, weight gain, and jaundice, and is considered a major PBSCs by significantly lowering the risk of GVHD. Since its first transplant for Fanconi's anemia in 1988, limiting factor for both auto-and allo-SCT and, like GVHD, benefits more from prophylaxis than therapy.
cord blood has been a highly promising source for SCT. Most data are available from transplanted children, but Quality of life is an important factor in therapy determination; however, because SCT is usually reserved for research on cord blood transplantation for adults is currently ongoing. In the past decades, several cord blood advanced otherwise fatal diseases, quality of life doesn't enjoy a primary role. Factors like spiritual and physical transplants (CBTs) have been performed for malignant and nonmalignant disease. The fraction of primitive abilities, social well-being, and psychoemotional status are usually not factored in the therapy decision making.
CD34 + /CD38 − cells appears to be lower in cord blood grafts as opposed to BM allografts, but this cell fraction There is a need for large longitudinal studies to evaluate potential intervention to improve quality of life and re-generates more progenitors compared with bone marrow. Primitive cord blood transplantation has also de-late it to different kinds of therapy.
Because only 25-30% of patients have a suitable creased risks of infection and severity of GVHD. Neutrophil recovery is slower, but the 2-year survival HLA-genotypically identical sibling donor for transplant therapy, registries of volunteer marrow donors were es-probability of unrelated CBT is comparable to TCD-BMT and BM-methotrexate immune suppression. Inter-tablished in Europe and North America in the 1980s. The extreme polymorphism of the HLA system and the estingly, in unrelated CBT there is no statistical association between the grade of acute GVHD and the degree discrepancy of HLA phenotypes of different populations demanded a requirement for volunteer donor registries of HLA mismatching. Ex vivo cord blood expansion is promising for further future benefits. of substantial size and genetic diversity. Unrelated donor The last two chapters of the book examine ways to nonmyelablative BMT, despite short follow-up, are encouraging. Current challenges include defining the opti-modify or engineer the stem cell graft, to decrease graft versus host disease while maximizing the graft versus mal regimen to facilitate full donor engraftment while further minimizing regimen-related toxicities and the in-tumor effect. Tumor contamination of stem cell products is eradicated by purging. In addition to high-dose che-cidence of infection and GVHD. Such strategies would expand treatment options for patients who would other-motherapy used to overcome drug resistance in advanced stage malignancies, immunological methods are used to wise be eligible for potentially curative therapy with allo-HSCT. eradicate minimal and overt diseases from autologous HSCT. Clinical impact of immunological purging has
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